The University of Chicago Header Logo

Peter Riedell

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
Email
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Roloff GW, Kosuri S, Nawas MT, DuVall AS, Patel AA, Riedell PA, Odenike O, Stock W, Larson RA, Bishop MR, Nunley E, Godley LA, Hathaway F, Del Gaudio D, Das S, Canham LE, Drazer MW. Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744. PMID: 38618681; PMCID: PMC11532700.
      Citations:    Fields:    
    2. Ahmed N, Wesson W, Lutfi F, Porter DL, Bachanova V, Nastoupil LJ, Perales MA, Maziarz RT, Brower J, Shah GL, Chen AI, Oluwole OO, Schuster SJ, Bishop MR, McGuirk JP, Riedell PA, Ahmed N, Wesson W, Lutfi F, Porter DL, Bachanova V, Nastoupil LJ, Perales MA, Maziarz RT, Brower J, Shah GL, Chen AI, Oluwole OO, Schuster SJ, Bishop MR, McGuirk JP, Riedell PA. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 10 22; 8(20):5346-5354. PMID: 39042880.
      Citations: 1     Fields:    Translation:Humans
    3. Fowler NH, Chavez JC, Riedell PA. Correction to: Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review. Target Oncol. 2024 Sep; 19(5):817. PMID: 39028410; PMCID: PMC11392971.
      Citations:    Fields:    
    4. Yates SJ, Cursio JF, Artz A, Kordas K, Bishop MR, Derman BA, Kosuri S, Riedell PA, Kline J, Jakubowiak A, Mortel M, Johnson S, Nawas MT. Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797. PMID: 38810262; PMCID: PMC11298834.
      Citations:    Fields:    Translation:Humans
    5. Riedell PA. BsAbs before CD19 CAR-T: full speed ahead! Blood. 2024 07 18; 144(3):249-251. PMID: 39023866.
      Citations:    Fields:    Translation:Humans
    6. Ahmed G, Alsouqi A, Szabo A, Samples L, Shadman M, Awan FT, Rojek AE, Riedell PA, Iqbal M, Fenske TS, Kharfan-Dabaja MA, Ito S, Hamadani M. CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024 07 09; 8(13):3528-3531. PMID: 38701405; PMCID: PMC11261102.
      Citations: 1     Fields:    Translation:Humans
    7. Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez J, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain JM, Ruiz M, Brammer JE, Prakash R, Iyer SP, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos B, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Brooks TR, Jagadeesh D, Hariharan N, Goodman AM, Hartman G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood Adv. 2024 07 09; 8(13):3507-3518. PMID: 38739715; PMCID: PMC11261035.
      Citations:    Fields:    Translation:HumansCells
    8. Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer J. 2024 07 08; 14(1):108. PMID: 38977682; PMCID: PMC11231252.
      Citations:    Fields:    Translation:Humans
    9. Fowler NH, Chavez JC, Riedell PA. Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review. Target Oncol. 2024 Jul; 19(4):495-510. PMID: 38896212; PMCID: PMC11271334.
      Citations: 1     Fields:    Translation:Humans
    10. Epperla N, Hashmi H, Ahn KW, Allbee-Johnson M, Chen AI, Wirk B, Kanakry JA, Lekakis L, Kharfan-Dabaja MA, Scordo M, Riedell PA, Jain T, Shadman M, Sauter C, Hamadani M, Herrera AF, Ahmed S. Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis. Br J Haematol. 2024 Sep; 205(3):1202-1207. PMID: 38797526; PMCID: PMC11499028.
      Citations:    Fields:    
    11. Alsouqi A, Ahmed G, Wang J, Szabo A, Rojek AE, Riedell PA, Awan F, Samples L, Shadman M, Hu M, Bachanova V, Wesson W, Ahmed N, Iqbal M, Kharfan-Dabaja MA, Scordo M, Johnson PC, Chen YB, Ito S, Hamadani M, Frigault M, Cassanello G. Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis. Am J Hematol. 2024 08; 99(8):1624-1627. PMID: 38769663.
      Citations: 1     Fields:    Translation:Humans
    12. Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, Hamadani M, Jimenez Jimenez A. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis. Leukemia. 2024 Jul; 38(7):1564-1569. PMID: 38750138; PMCID: PMC11271761.
      Citations:    Fields:    Translation:Humans
    13. Malladi R, Paule I, Zia A, Germano D, Maier HJ, Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, María Ferreri AJ, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Awasthi R, Han X, O'Donovan D, Ramos R, Masood A, Thieblemont C, Schuster SJ. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood. 2024 04 25; 143(17):1713-1725. PMID: 38194692; PMCID: PMC11103095.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    14. He G, Belmont E, Karrison T, Stock W, LaBelle JL, Kosuri S, Larson RA, Kline JP, Riedell PA, Nawas M, Bishop MR, Liu H. FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients. Ann Transl Med. 2024 Jun 10; 12(3):49. PMID: 38911560; PMCID: PMC11193555.
      Citations:    
    15. Fan H, Xia S, Xiang J, Li Y, Ross MO, Lim SA, Yang F, Tu J, Xie L, Dougherty U, Zhang FQ, Zheng Z, Zhang R, Wu R, Dong L, Su R, Chen X, Althaus T, Riedell PA, Jonker PB, Muir A, Lesinski GB, Rafiq S, Dhodapkar MV, Stock W, Odenike O, Patel AA, Opferman J, Tsuji T, Matsuzaki J, Shah H, Faubert B, Elf SE, Layden B, Bissonnette BM, He YY, Kline J, Mao H, Odunsi K, Gao X, Chi H, He C, Chen J. Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 Nov; 623(7989):1034-1043. PMID: 37993715; PMCID: PMC10686835.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    16. Riedell PA, Downs C, Boehmer L, Ebmeier J, Porter D, Williams A. If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary. Transplant Cell Ther. 2024 Jan; 30(1):14-16. PMID: 37918667.
      Citations:    Fields:    Translation:Humans
    17. Scordo M, Flynn JR, Gonen M, Devlin SM, Parascondola A, Tomas AA, Shouval R, Brower J, Porter DL, Schuster SJ, Bachanova V, Maakaron J, Maziarz RT, Chen AI, Nastoupil LJ, McGuirk JP, Oluwole OO, Ip A, Leslie LA, Bishop MR, Riedell PA, Perales MA. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023 09 26; 7(18):5579-5585. PMID: 37522731; PMCID: PMC10514205.
      Citations: 4     Fields:    Translation:Humans
    18. Rojek AE, Kline JP, Feinberg N, Appelbaum DE, Pu Y, Derman BA, Jakubowiak A, Kosuri S, Liu H, Nawas MT, Smith SM, Bishop MR, Riedell PA. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93. PMID: 37827881.
      Citations: 4     Fields:    Translation:Humans
    19. Bhaskar ST, Patel VG, Porter DL, Schuster SJ, Nastoupil LJ, Perales MA, Tomas AA, Bishop MR, McGuirk JP, Maziarz RT, Chen AI, Bachanova V, Maakaron JE, Riedell PA, Oluwole OO. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2023 09 12; 7(17):4765-4772. PMID: 36508286; PMCID: PMC10468356.
      Citations: 4     Fields:    Translation:Humans
    20. Czapka MT, Riedell PA, Pisano JC. Infectious complications of car T-cell therapy: A longitudinal risk model. Transpl Infect Dis. 2023 Nov; 25 Suppl 1:e14148. PMID: 37695203.
      Citations: 3     Fields:    Translation:Humans
    21. Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538. PMID: 37026796; PMCID: PMC10425681.
      Citations: 10     Fields:    Translation:Humans
    22. Wudhikarn K, Tomas AA, Flynn JR, Devlin SM, Brower J, Bachanova V, Nastoupil LJ, McGuirk JP, Maziarz RT, Oluwole OO, Schuster SJ, Porter DL, Bishop MR, Riedell PA, Perales MA. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2023 07 11; 7(13):3192-3198. PMID: 36355838; PMCID: PMC10338201.
      Citations: 13     Fields:    Translation:Humans
    23. Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaac KM, Portell CA, Mejia Garcia A, Goldsmith S, Grover NS, Riedell PA, Karmali R, Burkart M, Buege M, Akhtar O, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023 07 11; 7(13):2983-2993. PMID: 36809796; PMCID: PMC10320213.
      Citations: 5     Fields:    Translation:Humans
    24. Du Y, Jaeger U, Worel N, McGuirk JP, Riedell PA, Fleury I, Han X, Pearson D, Redondo S, Waller EK. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results. Blood Adv. 2023 06 13; 7(11):2283-2286. PMID: 36044388; PMCID: PMC10225880.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    25. Mahmood SS, Riedell PA, Feldman S, George G, Sansoterra SA, Althaus T, Rehman M, Mead E, Liu JE, Devereux RB, Weinsaft JW, Kim J, Balkan L, Barbar T, Lee Chuy K, Harchandani B, Perales MA, Geyer MB, Park JH, Palomba ML, Shouval R, Tomas AA, Shah GL, Yang EH, Gaut DL, Rothberg MV, Horn EM, Leonard JP, Van Besien K, Frigault MJ, Chen Z, Mehrotra B, Neilan TG, Steingart RM. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. 2023 Jun 09; 44(22):2029-2042. PMID: 36939851; PMCID: PMC10256191.
      Citations: 10     Fields:    Translation:Humans
    26. Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 08 19; 402(10402):641-654. PMID: 37295445.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    27. Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL, ZUMA-7 Investigators, Kite Members. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023 Jul 13; 389(2):148-157. PMID: 37272527.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    28. Ahmed N, Wesson W, Mushtaq MU, Porter DL, Nasta SD, Brower J, Bachanova V, Hu M, Nastoupil LJ, Oluwole OO, Patel VG, Oliai C, Riedell PA, Bishop MR, Shah GL, Perales MA, Schachter L, Maziarz RT, McGuirk JP. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023 07; 29(7):449.e1-449.e7. PMID: 37120134; PMCID: PMC11027185.
      Citations: 4     Fields:    Translation:Humans
    29. Godfrey J, Liu H, Yu J, Tallarico M, Curran E, Artz A, Riedell PA, Stock W, Karrison T, Fitzpatrick C, Venkataraman G, Cooper A, Smith SM, Bishop MR, Kline J. Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970. PMID: 35973200; PMCID: PMC10027501.
      Citations: 6     Fields:    Translation:HumansAnimals
    30. Tran MC, Hasan Y, Wang A, Yenice K, Partouche J, Stock W, Larson RA, Kosuri S, LaBelle JL, Kline J, Riedell PA, Artz AS, Weichselbaum R, Bishop MR, Aydogan B, Liu H. A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292. PMID: 35851593; PMCID: PMC9898602.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    31. Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, Bachanova V, Oluwole OO, Brower J, Flores OA, Ahmed N, Schachter L, Bharucha K, Dholaria BR, Schuster SJ, Perales MA, Bishop MR, Porter DL. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplant Cell Ther. 2022 10; 28(10):669-676. PMID: 35850429; PMCID: PMC9547952.
      Citations: 23     Fields:    Translation:Humans
    32. Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022 08; 23(8):1066-1077. PMID: 35839786.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    33. Tanager KS, Yu J, Chiu BC, Carll TC, Tatarian AH, Riedell P, Smith S, Kline J, Venkataraman G. Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators. Haematologica. 2022 04 01; 107(4):966-969. PMID: 34911281; PMCID: PMC8968890.
      Citations:    Fields:    Translation:Humans
    34. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806. PMID: 34699592; PMCID: PMC10652916.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    35. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC, Thieblemont C. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022 04; 28(4):735-742. PMID: 35314842; PMCID: PMC9018426.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    36. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Kato K, Harigae H, Andreadis C, Riedell PA, Ho PJ, Chen AI, Nastoupil LJ, von Tresckow B, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Bachy E, Kersten MJ, Pérez-Simón JA, Ferreri AJM, Zinzani PL, Thieblemont C. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022 02; 28(2):325-332. PMID: 34921238.
      Citations: 148     Fields:    Translation:HumansCTClinical Trials
    37. Locke FL, Miklos DB, Jacobson CA, Perales MA, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All ZUMA-7 Investigators and Contributing Kite Members, Kersten MJ, Muñoz J. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 02 17; 386(7):640-654. PMID: 34891224.
      Citations: 412     Fields:    Translation:HumansCTClinical Trials
    38. Hu Y, Cao G, Chen X, Huang X, Asby N, Ankenbruck N, Rahman A, Thusu A, He Y, Riedell PA, Bishop MR, Schreiber H, Kline JP, Huang J. Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents. Matter. 2021 Dec 01; 4(12):3917-3940. PMID: 34901832; PMCID: PMC8654235.
      Citations: 2     
    39. Riedell PA, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM, Hamadani M, Ahn KW, Litovich C. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. Br J Haematol. 2021 12; 195(5):757-763. PMID: 34581433; PMCID: PMC8627449.
      Citations: 3     Fields:    Translation:Humans
    40. Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSG, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, Nishihori T, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 11; 27(11):911.e1-911.e7. PMID: 34450333; PMCID: PMC8556305.
      Citations: 6     Fields:    Translation:Humans
    41. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021 Jul 01; 7(7):993-1003. PMID: 33956047; PMCID: PMC8283558.
      Citations: 20     Fields:    Translation:Humans
    42. Trujillo JA, Godfrey J, Hu Y, Huang J, Smith SM, Frigault MJ, DeFilipp Z, Appelbaum D, Pu Y, Feinberg N, Althaus T, Bishop MR, Riedell PA, Kline J. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459. PMID: 33881502; PMCID: PMC8212512.
      Citations: 6     Fields:    Translation:HumansCells
    43. Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR. Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. Leuk Lymphoma. 2021 06; 62(6):1497-1501. PMID: 33535838.
      Citations:    Fields:    Translation:Humans
    44. Riedell PA, Kline JP, Gideon JM, Wickrema A, Bishop MR. Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials. Transplant Cell Ther. 2021 02; 27(2):105-107. PMID: 33781544.
      Citations:    Fields:    
    45. Derman BA, Kordas K, Molloy E, Chow S, Dale W, Jakubowiak AJ, Jasielec J, Kline JP, Kosuri S, Lee SM, Liu H, Riedell PA, Smith SM, Bishop MR, Artz AS. Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591. PMID: 33162369.
      Citations: 6     Fields:    Translation:Humans
    46. Riedell PA. Advances in CAR T-Cell Therapy for Aggressive B-NHL. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S94-S97. PMID: 32862885.
      Citations:    Fields:    Translation:Humans
    47. Bachanova V, Bishop MR, Dahi P, Dholaria B, Grupp SA, Hayes-Lattin B, Janakiram M, Maziarz RT, McGuirk JP, Nastoupil LJ, Oluwole OO, Perales MA, Porter DL, Riedell PA, CAR T-cell Consortium. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Transplant. 2020 07; 26(7):1239-1246. PMID: 32298807; PMCID: PMC7194685.
      Citations: 39     Fields:    Translation:HumansCellsPHPublic Health
    48. Wang AY, Kline J, Stock W, Kosuri S, Artz A, Larson RA, Riedell PA, Bishop M, Liu H. Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027. PMID: 32018063.
      Citations: 17     Fields:    Translation:Humans
    49. Riedell PA, Bishop MR. Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. Ther Adv Hematol. 2020; 11:2040620720902899. PMID: 32064069; PMCID: PMC6990602.
      Citations: 8     
    50. Kothari S, Artz AS, Lee SM, Fulton N, Park JH, Stock W, Larson RA, Odenike O, Kline J, LaBelle J, Kosuri S, Riedell P, Nakamura Y, Bishop MR, Liu H. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168. PMID: 31992847.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    51. Derman BA, Kordas K, Ridgeway J, Chow S, Dale W, Lee SM, Aguada E, Jakubowiak AJ, Jasielec J, Kline J, Kosuri S, Larson RA, Liu H, Mortel M, Odenike O, Pisano J, Riedell P, Stock W, Bishop MR, Artz AS. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498. PMID: 31725894; PMCID: PMC6880895.
      Citations: 30     Fields:    Translation:Humans
    52. Abboud R, Chendamarai E, Rettig MP, Trinkaus KM, Riedell PA, Abboud CN, Ghobadi A, Pusic I, Stockerl-Goldstein K, Schroeder MA, Vij R, Westervelt P, DiPersio JF, Uy GL. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica. 2020 08; 105(8):e404-e407. PMID: 31753931; PMCID: PMC7395277.
      Citations: 7     Fields:    Translation:HumansAnimalsCTClinical Trials
    53. Cahill KE, Leukam MJ, Riedell PA. Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. Leuk Lymphoma. 2020 04; 61(4):799-807. PMID: 31750749.
      Citations: 5     Fields:    Translation:HumansCells
    54. Riedell PA, Smith SM. Double hit and double expressors in lymphoma: Definition and treatment. Cancer. 2018 12 15; 124(24):4622-4632. PMID: 30252929.
      Citations: 86     Fields:    Translation:HumansCells
    55. Lukas RV, Riedell P, Horowitz PM, Pytel P, Kamson DO. Diagnostic Evaluation in Primary CNS Lymphoma. Neurologist. 2018 Mar; 23(2):53-54. PMID: 29494436.
      Citations: 1     Fields:    Translation:Humans
    56. Riedell PA, Smith SM. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL? Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):91-97. PMID: 29352717.
      Citations: 1     Fields:    Translation:HumansCells
    57. Riedell PA, Bishop MR. Post-autologous transplant maintenance therapies in lymphoma: current state and future directions. Bone Marrow Transplant. 2018 01; 53(1):11-21. PMID: 28967896.
      Citations: 1     Fields:    Translation:Humans
    58. Xiao DY, Luo S, O'Brian K, Ganti A, Riedell P, Sanfilippo KM, Lynch RC, Liu W, Carson KR. Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Am J Hematol. 2016 10; 91(10):1002-7. PMID: 27356783; PMCID: PMC5324973.
      Citations: 18     Fields:    Translation:Humans
    59. Xiao DY, Luo S, O'Brian K, Sanfilippo KM, Ganti A, Riedell P, Lynch RC, Liu W, Kahl BS, Cashen AF, Fehniger TA, Carson KR. Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans. J Natl Cancer Inst. 2016 11; 108(11). PMID: 27381623; PMCID: PMC5241900.
      Citations: 10     Fields:    Translation:Humans
    60. Sanfilippo KM, Wang TF, Gage BF, Luo S, Riedell P, Carson KR. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. Thromb Res. 2016 Jul; 143:86-90. PMID: 27208462; PMCID: PMC4920731.
      Citations: 19     Fields:    Translation:Humans
    61. Lu C, Riedell P, Miller CA, Hagemann IS, Westervelt P, Ozenberger BA, O'Laughlin M, Magrini V, Demeter RT, Duncavage EJ, Griffith M, Griffith OL, Wartman LD. A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia. Cold Spring Harb Mol Case Stud. 2016 Jan; 2(1):a000687. PMID: 27148581; PMCID: PMC4849848.
      Citations: 13     Fields:    
    62. O'Brian K, Luo S, Ganti A, Riedell P, Lynch RC, Roop R, Sanfilippo KM, Liu W, Colditz GA, Carson KR. Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Leuk Lymphoma. 2016 Feb; 57(2):313-319. PMID: 26085202; PMCID: PMC4752439.
      Citations: 3     Fields:    
    63. Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, Colditz GA. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. J Geriatr Oncol. 2015 May; 6(3):211-8. PMID: 25614297; PMCID: PMC4605388.
      Citations: 24     Fields:    Translation:Humans
    64. Ganti A, Liu W, Luo S, Sanfilippo KM, Roop R, Lynch R, Riedell P, O'Brian K, Colditz GA, Carson KR. Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. Br J Haematol. 2014 Dec; 167(5):699-702. PMID: 25040880; PMCID: PMC4605387.
      Citations: 7     Fields:    Translation:Humans
    65. Riedell P, Carson KR. A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf. 2014 Jul; 13(7):977-87. PMID: 24821316.
      Citations: 4     Fields:    Translation:HumansCells
    Riedell's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (164)
    Explore
    _
    Co-Authors (47)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _